A biologic injection that reduces chronic obstructive pulmonary disease (COPD) flare-ups by around a third has been approved for use on the NHS in England and Wales. The National Institute for Health ...
NICE has recommended dupilumab for adults with uncontrolled COPD and raised eosinophils, citing fewer exacerbations and ...
Dupilumab, a simple pre-filled pen that people inject themselves with every two weeks, is the first biologic that targets both the symptoms of COPD and an underlying cause of the disease. It brings ...
NICE has estimated that around 40% of people with COPD have elevated blood levels of eosinophils and, if half the eligible ...
The National Institute for Health and Care Excellence (NICE), has published final draft guidance recommending dupilumab as a ...
Among patients with blood eosinophil counts greater than or equal to 150 cells/µL, the reduction in the annual rate of moderate to severe COPD exacerbations was found to be nominally significant. The ...
Verona Pharma is off to a promising start as it launches its first product, Ohtuvayre, a maintenance treatment for chronic obstructive pulmonary disorder (COPD). In 2024, Ohtuvayre generated sales of ...
The blockbuster Sanofi and Regeneron Pharmaceuticals drug Dupixent, already commercialized in several skin and lung disorders, has expanded its FDA-approval to chronic obstructive pulmonary disease ...
The FDA approved Ohtuvayre (ensifentrine) as a maintenance therapy for COPD (chronic obstructive pulmonary disease). The medication works as both a bronchodilator and an anti-inflammatory to ease ...
COPD requires regular monitoring through tests like spirometry to assess the condition’s severity and aid in an individualized treatment plan. COPD is a progressive lung condition that makes breathing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results